Liberated?

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-04-01-2001
Volume 0
Issue 0

Patents before profits. That soundbite snagged my ears and turned my full attention to the CNN business report. I recognized the voice and the face}Ray Gilmartin, chairman of Merck. Calmly and reasonably, he explained how extraordinary circumstances in the developing world demand that his company uncouple the normally fused objectives of high profitability and unwavering patent protection.

Articles in this issue
Annual Reports: Size Doesn't Matter
Internet DTC - Minding Your P's & Q's
Regulation: Two-Track Plan
Policy: Tectonic Shift
Liberated?
A Matter of Taste
Partnerships: Bargaining Biotechs
Pediatric Mandate
Genentech's Passion for Patients
Regulation: OK After All
Beyond Training
Balancing Haves & Have-Nots
The Changing OTC Landscape
Recent Videos
Marcel Botha, 10XBeta
Jennifer Kyle, Condor
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Related Content
March Pharmaceutical Industry Movers & Shakers

March Pharmaceutical Industry Movers & Shakers

Miranda Schmalfuhs
March 31st 2025
Article

A monthly roundup of business and people news in the pharmaceutical industry.

Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC

Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC

Don Tracy, Associate Editor
March 31st 2025
Article

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% compared to standard care in patients with epidermal growth factor receptor-mutated non-small cell lung cancer.

Jennifer Butler

The Misinformation Maze: Navigating Public Health in the Digital Age

Miranda Schmalfuhs
March 11th 2025
Podcast

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

Novo Nordisk Reaches Licensing Deal with Lexicon Pharmaceuticals for Novel Obesity Candidate

Novo Nordisk Reaches Licensing Deal with Lexicon Pharmaceuticals for Novel Obesity Candidate

Don Tracy, Associate Editor
March 28th 2025
Article

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity and metabolic disorders.

Credit: WrightStudio | stock.adobe.com

Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success

Shana Gunderson Hua, PharmD; Nancy Pham, PharmD; and Pete Vaccaro
March 28th 2025
Article

The high-stakes nature of cancer care, coupled with rapid scientific advancements and increasing payer and regulatory pressures, demands a specialized approach beyond traditional market access strategies.